Physician profile
Katie Levitt
NPI 1497300826
$1,120.81
in general payments reported to CMS, 2019-2025
10 companies · $32.62 in 2025
The $32.62 reported for 2025 was less than what a typical Critical Care Medicine (Registered Nurse) provider received nationally (typical 2025 total: $51.32).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $233 · 2022: $182 · 2023: $476 · 2024: $196 · 2025: $32.62.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $705.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $704.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $320.16 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $210.16 | 2022-2024 | Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $179.92 | 2023-2025 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $138.83 | 2021-2022 | |
| Amgen INC. | $112.96 | 2022-2024 | Repatha |
| Galderma Laboratories, L.P. | $63.35 | 2024 | |
| Janssen Pharmaceuticals, INC | $27.94 | 2024 | Xarelto |
| Abiomed | $26.36 | 2023 | Impella |
| Kiniksa Pharmaceuticals International, Plc | $23.00 | 2024 | Arcalyst |
| Astrazeneca Pharmaceuticals LP | $18.13 | 2024 | Farxiga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katie Levitt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.